Advanced search    

Search: authors:"Leonardo Fabbri"

7 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease

Background Long-acting muscarinic antagonist/long-acting β 2 -agonist combinations are recommended for patients whose chronic obstructive pulmonary disease (COPD) is not managed with monotherapy. We assessed the efficacy and safety of glycopyrrolate (GP)/formoterol fumarate (FF) fixed-dose combination delivered via a Co-Suspension™ Delivery Technology-based metered dose inhaler ...

Insights, attitudes, and perceptions about asthma and its treatment: a multinational survey of patients from Europe and Canada

Background Asthma surveys completed within the past 10 years in the Americas and the Asia-Pacific region have shown significant underassessment of asthma severity in addition to undertreatment of asthma and have suggested the need to improve long-term asthma management. In this study, we examined the frequency of asthma symptoms and severe episodes, patients’ perceived asthma ...

Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD

Background This study forms part of the first complete characterization of the dose–response curve for glycopyrrolate (GP) delivered using Co-Suspension™ Delivery Technology via a metered dose inhaler (MDI). We examined the lower GP MDI dose range to determine an optimal dose for patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). Methods This randomized, ...

The Burden of Image Based Emphysema and Bronchiolitis in HIV-Infected Individuals on Antiretroviral Therapy

support or funding to report. Competing Interests: The authors confirm that co-author Leonardo Fabbri is a PLOS ONE Editorial Board member. However, this does not alter the authors adherence to PLOS ONE

Step-down from high dose fixed combination therapy in asthma patients: a randomized controlled trial

BackgroundAsthma guidelines suggest that therapy can be reduced once asthma is controlled. Despite these recommendations, asthmatic patients are seldom stepped down in clinical practice, and questions remain about when and how to reduce asthma therapy. The purpose of the present study was to evaluate lung function and asthma control in patients who were stepped down from the ...

Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease

Paul W Jones 0 Stephen I Rennard Alvar Agusti Pascal Chanez Helgo Magnussen Leonardo Fabbri James F Donohue Eric D Bateman Nicholas J Gross Rosa Lamarca Cynthia Caracta Esther Garcia Gil 0 St

Systems medicine and integrated care to combat chronic noncommunicable diseases

Brambilla Jacques Bringer Michel Dauzat Ingemar Ernberg Leonardo Fabbri Philippe Froguel David Galas Takashi Gojobori Peter Hunter Christian Jorgensen Francine Kau mann Philippe Kourilsky Marek L Kowalski